Filing Details
- Accession Number:
- 0001567619-21-018312
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-14 18:16:06
- Reporting Period:
- 2021-10-12
- Accepted Time:
- 2021-10-14 18:16:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1770787 | 10X Genomics Inc. | TXG | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1246406 | Bradford Crutchfield | C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2021-10-12 | 17,000 | $1.16 | 60,336 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2021-10-12 | 5,960 | $156.49 | 54,376 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-10-12 | 7,997 | $157.40 | 46,379 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-10-12 | 3,043 | $158.63 | 43,336 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (right to buy) | Disposition | 2021-10-12 | 17,000 | $0.00 | 17,000 | $1.16 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 460,000 | 2027-02-03 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $155.95 to $156.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $156.95 to $157.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $158.09 to $159.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This option, originally for 800,000 shares, of which 340,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Billionaire Hedge Funds
